Adaptimmune Therapeutics/ADAP

$1.10

-
-
1D1W1MYTD1YMAX

About Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Ticker

ADAP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adrian Rawcliffe

Employees

449

Headquarters

Abingdon, United Kingdom

ADAP Metrics

BasicAdvanced
$284M
Market cap
-
P/E ratio
-$0.73
EPS
2.31
Beta
-
Dividend rate
$284M
2.3143
$2.05
$0.42
1.5M
2.814
-59.85%
-301.91%
-78.55%
15.452
11.635
11.894
-74.21%
-3.66%
147.88%

What the Analysts think about ADAP

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
127.27% upside
High $4.00
Low $1.00
$1.10
Current price
$2.50
Average price target

ADAP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-866.07% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$5.6M
2,700%
Net income
-$49M
1.25%
Profit margin
-866.07%
-96.38%

ADAP Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 83.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.12
-$0.20
-$0.24
-$0.18
-
Expected
-$0.13
-$0.12
-$0.10
-$0.10
-$0.11
Surprise
-9.87%
72.41%
140%
83.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Adaptimmune Therapeutics stock?

Adaptimmune Therapeutics (ADAP) has a market cap of $284M as of May 22, 2024.

What is the P/E ratio for Adaptimmune Therapeutics stock?

The price to earnings (P/E) ratio for Adaptimmune Therapeutics (ADAP) stock is 0 as of May 22, 2024.

Does Adaptimmune Therapeutics stock pay dividends?

No, Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Adaptimmune Therapeutics dividend payment date?

Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders.

What is the beta indicator for Adaptimmune Therapeutics?

Adaptimmune Therapeutics (ADAP) has a beta rating of 2.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Adaptimmune Therapeutics stock price target?

The target price for Adaptimmune Therapeutics (ADAP) stock is $2.5, which is 131.48% above the current price of $1.08. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Adaptimmune Therapeutics stock

Buy or sell Adaptimmune Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing